ISI Provides Color on Biogen Idec

ISI provided color on Biogen Idec BIIB. In a research report published today, ISI is optimistic about the company's new drug, which has the potential of outperforming its competitors. In the report, ISI states, “Abstracts for the ISTH meeting are out. For BIIB, the most important is the first description of phase I/II data for the company's long acting factor 8 program. The abstract says that the half-life is prolonged 66%-68% (depending on the assay) versus Baxter's Advate.” On Tuesday, Biogen lost 1.31% of its value to finish the day at $104.05.